Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure

American Journal of Cardiology

Volumn 104, Issue 12, 2009, Pages 1708-1716

  Lipinski, Michael J ^a   Cauthen, Clay A ^a   Biondi Zoccai, Giuseppe G L ^c   Abbate, Antonio ^b   Vrtovec, Bojan ^d   Khan, Bobby V ^e   Vetrovec, George W ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIVER DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; MUSCLE DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TREATMENT OUTCOME;

EID: 70749119012     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.055     Document Type: Article

References (34)

1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
2. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., Macfadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., and Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
5. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
6. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., and Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
7. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
8. Ray J.G., Gong Y., Sykora K., and Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
9. Scirica B.M., Morrow D.A., Cannon C.P., Ray K.K., Sabatine M.S., Jarolim P., Shui A., McCabe C.H., and Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47 (2006) 2326-2331
10. Khush K.K., Waters D.D., Bittner V., Deedwania P.C., Kastelein J.J., Lewis S.J., and Wenger N.K. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115 (2007) 576-583
11. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., Ramsey K.E., Palmisano J., Bilheimer D.W., Pfeffer M.A., Califf R.M., and Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
12. Lipinski M.J., Abbate A., Fuster V., and Vetrovec G.W. Drug insight: statins for nonischemic heart failure-evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 4 (2007) 196-205
13. Vrtovec B., Okrajsek R., Golicnik A., Ferjan M., Starc V., Schlegel T.T., and Radovancevic B. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 14 (2008) 140-144
14. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
15. Yamada T., Node K., Mine T., Morita T., Kioka H., Tsukamoto Y., Tamaki S., Masuda M., Okuda K., and Fukunami M. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153 suppl (2007) e1051-e1058
16. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
17. Wojnicz R., Wilczek K., Nowalany-Kozielska E., Szyguła-Jurkiewicz B., Nowak J., Poloński L., Dyrbuś K., Badziński A., Mercik G., Zembala M., Wodniecki J., and Rozek M.M. Usefulness of atorvastatin in patients with heart failure due to Inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97 (2006) 899-904
18. Xie R.Q., Cui W., Liu F., Yang C., Pei W.N., and Lu J.C. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol (2008) [Epub ahead of print]
19. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Janosi A., Kamensky G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J.J., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D.J., Waagstein F., Wedel H., and Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
20. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., and Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
21. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
22. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
23. Deeks J.J., Altman D.G., and Bradburn M.J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in Health Care: Meta-Analysis in Context (2001), BMJ Publishing, London 285-312
24. Kendrach M.G., and Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 38 (2004) 1286-1292
25. Hamaad A., Sosin M., Lip G.Y., and MacFadyen R.J. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 19 (2005) 183-187
26. Krum H., Ashton E., Reid C., Kalff V., Rogers J., Amarena J., Singh B., and Tonkin A. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13 (2007) 1-7
27. Nezasa K., Higaki K., Matsumura T., Inazawa K., Hasegawa H., Nakano M., and Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 30 (2002) 1158-1163
28. Ford J.S., and Tayek J.A. Lipophilicity and cardiovascular outcome in patients with CHF. Am Heart J 156 (2008) e7
29. Davidson M.H., Clark J.A., Glass L.M., and Kanumalla A. Statin safety: an appraisal from the Adverse Event reporting System. Am J Cardiol 97 suppl (2006) 32C-43C
30. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19 (2005) 117-125
31. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
32. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
33. LaRosa J.C., Grundy S.M., Kastelein J.J., Kostis J.B., and Greten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol 100 (2007) 747-752
34. Singh U., Devaraj S., Jialal I., and Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 102 (2008) 321-325